Hyderabad-based pharmaceutical major Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to make abacavir sulfate and lamivudine tablets, which are used in the treatment of HIV.
“The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture abacavir sulfate and lamivudine tablets, 600 mg/ 300 mg,” the company said in a BSE filing.
The product, with an estimated market size of $388 million, will be launched immediately, according to the Indian pharma major.
With this, Aurobindo Pharma now has a total of 314 ANDA approvals from the US drug regulator.
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.